Early Clinical Effects of Novel Partial D3/D2 Agonist Cariprazine in Schizophrenia Patients With Predominantly Negative Symptoms (Open-Label, Non-controlled Study)

Bibliographic Data

ID15517643
AuthorsС В Иванов (0000-0001-9532-7150, Mental Health Research Center of Russian Academy of Medical Sciences, corresponding author), Stanislav V Ivanov, Smulevich Ab (0000-0003-2737-3432, Sechenov University), Anatoly B Smulevich, Е И Воронова (0000-0001-6605-4851, Mental Health Research Center of Russian Academy of Medical Sciences), Evgeniya I Voronova, К К Yakhin (0000-0001-5958-5355, Kazan State Medical University), Kausar K Yakhin, Tangyul Z Beybalaeva (0000-0002-5262-6852, Kazan State Medical University), Alena A Katok (0000-0001-9046-3532, Kazan State Medical University)
Year2022
Volume12
Pages770592-770592
Publication date2022-01-24
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueFrontiers in Psychiatry (JOURNAL)
Journal identifiersISSN: 1664-0640 • E-ISSN: 1664-0640
PublisherFrontiers Media (PUBLISHER • CH)
DOI10.3389/fpsyt.2021.770592
PMID35140638
OpenAlexW4210323406
LanguageEN
Citations received2
References cited15

The results of this study suggest early effect of cariprazine on negative symptoms at least in some schizophrenia patients with predominantly negative symptoms starting from 1 to 2 weeks of treatment and could be useful for determination of early clinical predictors for efficacy. Considering limitations of open-label design with no control groups these data need to be confirmed

Adverse effect · Agonist · Akathisia · Antipsychotic · Dopamine · Dopamine receptor D2 · Dopamine receptor D3 · Extrapyramidal symptoms · Lurasidone · Partial agonist · Positive and Negative Syndrome Scale · Psychiatry · Psychosis · Receptor · Risperidone · Schizophrenia (object-oriented programming · Tolerability · Medicine · Neurotransmitter Receptor Influence on Behavior · Psychology · Schizophrenia research and treatment · Tryptophan and brain disorders · Internal Medicine

Tools

Open DOIOpen Access